Pharma and Biotech
By Iain Gilbert
Date: Monday 15 Oct 2018
LONDON (ShareCast) - (Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement industry giant Johnson and Johnson to develop a model of systemic lupus erythematosus, the most common form of Lupus.
J&J's Janssen Research and Development subsidiary inked the with Hemogenyx's Immugenyx subsidiary, will use its advanced hematopoietic chimeras, a new type of humanised mouse with a functional human immune system used for disease modelling and drug development.
The pair will collaborate on research activities to be determined by a mutually approved research plan. Immugenyx will own the humanised mouse model and grant Janssen and its affiliates a perpetual, irrevocable, non-exclusive, fully paid-up, transferable, worldwide, license to use the model for their own internal research and product development purposes.
Chief executive Dr Vladislav Sandler said: "As a company committed to the development of novel therapeutic products for patients suffering from blood and severe autoimmune diseases, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for autoimmune diseases."
As of 0830 BST, fully listed Hemogenyx shares had shot up 12.50% to 2.92p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 1.65p |
Change Today | 0.018p |
% Change | 1.11 % |
52 Week High | 3.96 |
52 Week Low | 1.17 |
Volume | 2,733,785 |
Shares Issued | 1,341.82m |
Market Cap | £22.10m |
RiskGrade | 340 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
10:45 | 50,000 @ 1.63p |
10:17 | 123,086 @ 1.63p |
10:15 | 73,879 @ 1.66p |
10:06 | 540 @ 1.63p |
10:02 | 2,230 @ 1.63p |
You are here: research